Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences

Globe Newswire December 2, 2013

Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA

ACCESS Newswire November 27, 2013

European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi® for the Treatment of Chronic Hepatitis C Infection

Business Wire November 22, 2013

Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study

Business Wire November 18, 2013

European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection

Business Wire November 18, 2013

Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13

Business Wire November 12, 2013

Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting

Business Wire November 7, 2013

Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation

Business Wire November 2, 2013

Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV

Business Wire November 2, 2013

Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients

Business Wire November 2, 2013

Gilead Sciences Announces Third Quarter 2013 Financial Results

Business Wire October 29, 2013

FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection

Business Wire October 25, 2013

Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013

Business Wire October 22, 2013

Five Star Equities Issues New Research Reports on BYD, CTXS, GILD and RT

ACCESS Newswire October 21, 2013

Gilead's Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy

Business Wire October 16, 2013

Galectin Stands Out in 2013 with Liver Fibrosis Drug

ACCESS Newswire October 14, 2013

Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit

Business Wire October 9, 2013

European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Business Wire September 25, 2013

Gilead's Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase 2 Study

Business Wire September 12, 2013

Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent Non-Hodgkin's Lymphoma

Business Wire September 11, 2013